A randomized placebo-controlled trial of convalescent plasma for adults hospitalized with COVID-19 pneumonia

Department of Immunology and Microbiology

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

A randomized placebo-controlled trial of convalescent plasma for adults hospitalized with COVID-19 pneumonia. / Thorlacius-Ussing, Louise; Brooks, Patrick Terrence; Nielsen, Henrik; Jensen, Bitten Aagaard; Wiese, Lothar; Sækmose, Susanne Gjørup; Johnsen, Stine; Gybel-Brask, Mikkel; Johansen, Isik S.; Bruun, Mie Topholm; Stærke, Nina Breinholdt; Østergaard, Lars; Erikstrup, Christian; Ostrowski, Sisse Rye; Homburg, Keld Mikkelsen; Georgsen, Jørgen; Mikkelsen, Susan; Sandholdt, Håkon; Leding, Cæcilie; Hovmand, Nichlas; Clausen, Clara Lundetoft; Tinggaard, Michaela; Pedersen, Karen Brorup Heje; Iversen, Katrine Kjær; Tingsgård, Sandra; Israelsen, Simone Bastrup; Benfield, Thomas.

In: Scientific Reports, Vol. 12, 16385, 2022.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Thorlacius-Ussing, L, Brooks, PT, Nielsen, H, Jensen, BA, Wiese, L, Sækmose, SG, Johnsen, S, Gybel-Brask, M, Johansen, IS, Bruun, MT, Stærke, NB, Østergaard, L, Erikstrup, C, Ostrowski, SR, Homburg, KM, Georgsen, J, Mikkelsen, S, Sandholdt, H, Leding, C, Hovmand, N, Clausen, CL, Tinggaard, M, Pedersen, KBH, Iversen, KK, Tingsgård, S, Israelsen, SB & Benfield, T 2022, 'A randomized placebo-controlled trial of convalescent plasma for adults hospitalized with COVID-19 pneumonia', Scientific Reports, vol. 12, 16385. https://doi.org/10.1038/s41598-022-19629-z

APA

Thorlacius-Ussing, L., Brooks, P. T., Nielsen, H., Jensen, B. A., Wiese, L., Sækmose, S. G., Johnsen, S., Gybel-Brask, M., Johansen, I. S., Bruun, M. T., Stærke, N. B., Østergaard, L., Erikstrup, C., Ostrowski, S. R., Homburg, K. M., Georgsen, J., Mikkelsen, S., Sandholdt, H., Leding, C., ... Benfield, T. (2022). A randomized placebo-controlled trial of convalescent plasma for adults hospitalized with COVID-19 pneumonia. Scientific Reports, 12, [16385]. https://doi.org/10.1038/s41598-022-19629-z

Vancouver

Thorlacius-Ussing L, Brooks PT, Nielsen H, Jensen BA, Wiese L, Sækmose SG et al. A randomized placebo-controlled trial of convalescent plasma for adults hospitalized with COVID-19 pneumonia. Scientific Reports. 2022;12. 16385. https://doi.org/10.1038/s41598-022-19629-z

Author

Thorlacius-Ussing, Louise ; Brooks, Patrick Terrence ; Nielsen, Henrik ; Jensen, Bitten Aagaard ; Wiese, Lothar ; Sækmose, Susanne Gjørup ; Johnsen, Stine ; Gybel-Brask, Mikkel ; Johansen, Isik S. ; Bruun, Mie Topholm ; Stærke, Nina Breinholdt ; Østergaard, Lars ; Erikstrup, Christian ; Ostrowski, Sisse Rye ; Homburg, Keld Mikkelsen ; Georgsen, Jørgen ; Mikkelsen, Susan ; Sandholdt, Håkon ; Leding, Cæcilie ; Hovmand, Nichlas ; Clausen, Clara Lundetoft ; Tinggaard, Michaela ; Pedersen, Karen Brorup Heje ; Iversen, Katrine Kjær ; Tingsgård, Sandra ; Israelsen, Simone Bastrup ; Benfield, Thomas. / A randomized placebo-controlled trial of convalescent plasma for adults hospitalized with COVID-19 pneumonia. In: Scientific Reports. 2022 ; Vol. 12.

Bibtex

@article{7d15a9cb7441485e83520c9aec345e56,

title = "A randomized placebo-controlled trial of convalescent plasma for adults hospitalized with COVID-19 pneumonia",

abstract = "Passive immunotherapy with convalescent plasma may be the only available agent during the early phases of a pandemic. Here, we report safety and efficacy of high-titer convalescent plasma for COVID-19 pneumonia. Double-blinded randomized multicenter placebo-controlled trial of adult patients hospitalized with COVID-19 pneumonia. The intervention was COVID-19 convalescent plasma and placebo was saline allocated 2:1. The primary outcome was clinical status 14 days after the intervention evaluated on a clinical ordinal scale. The trial was registered at ClinicalTrials.Gov, NCT04345289, 14/04/2020. The CCAP-2 trial was terminated prematurely due to futility. Of 147 patients randomized, we included 144 patients in the modified intention-to-treat population. The ordinal clinical status 14 days post-intervention was comparable between treatment groups (odds ratio (OR) 1.41, 95% confidence interval (CI) 0.72–2.09). Results were consistent when evaluating clinical progression on an individual level 14 days after intervention (OR 1.09; 95% CI 0.46–1.73). No significant differences in length of hospital stay, admission to ICU, frequency of severe adverse events or all-cause mortality during follow-up were found between the intervention and the placebo group. Infusion of convalescent plasma did not influence clinical progression, survival or length of hospitalization in patients with COVID-19 pneumonia.",

author = "Louise Thorlacius-Ussing and Brooks, {Patrick Terrence} and Henrik Nielsen and Jensen, {Bitten Aagaard} and Lothar Wiese and S{\ae}kmose, {Susanne Gj{\o}rup} and Stine Johnsen and Mikkel Gybel-Brask and Johansen, {Isik S.} and Bruun, {Mie Topholm} and St{\ae}rke, {Nina Breinholdt} and Lars {\O}stergaard and Christian Erikstrup and Ostrowski, {Sisse Rye} and Homburg, {Keld Mikkelsen} and J{\o}rgen Georgsen and Susan Mikkelsen and H{\aa}kon Sandholdt and C{\ae}cilie Leding and Nichlas Hovmand and Clausen, {Clara Lundetoft} and Michaela Tinggaard and Pedersen, {Karen Brorup Heje} and Iversen, {Katrine Kj{\ae}r} and Sandra Tingsg{\aa}rd and Israelsen, {Simone Bastrup} and Thomas Benfield",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

doi = "10.1038/s41598-022-19629-z",

language = "English",

volume = "12",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "nature publishing group",

}

RIS

TY - JOUR

T1 - A randomized placebo-controlled trial of convalescent plasma for adults hospitalized with COVID-19 pneumonia

AU - Thorlacius-Ussing, Louise

AU - Brooks, Patrick Terrence

AU - Nielsen, Henrik

AU - Jensen, Bitten Aagaard

AU - Wiese, Lothar

AU - Sækmose, Susanne Gjørup

AU - Johnsen, Stine

AU - Gybel-Brask, Mikkel

AU - Johansen, Isik S.

AU - Bruun, Mie Topholm

AU - Stærke, Nina Breinholdt

AU - Østergaard, Lars

AU - Erikstrup, Christian

AU - Ostrowski, Sisse Rye

AU - Homburg, Keld Mikkelsen

AU - Georgsen, Jørgen

AU - Mikkelsen, Susan

AU - Sandholdt, Håkon

AU - Leding, Cæcilie

AU - Hovmand, Nichlas

AU - Clausen, Clara Lundetoft

AU - Tinggaard, Michaela

AU - Pedersen, Karen Brorup Heje

AU - Iversen, Katrine Kjær

AU - Tingsgård, Sandra

AU - Israelsen, Simone Bastrup

AU - Benfield, Thomas

PY - 2022

Y1 - 2022

N2 - Passive immunotherapy with convalescent plasma may be the only available agent during the early phases of a pandemic. Here, we report safety and efficacy of high-titer convalescent plasma for COVID-19 pneumonia. Double-blinded randomized multicenter placebo-controlled trial of adult patients hospitalized with COVID-19 pneumonia. The intervention was COVID-19 convalescent plasma and placebo was saline allocated 2:1. The primary outcome was clinical status 14 days after the intervention evaluated on a clinical ordinal scale. The trial was registered at ClinicalTrials.Gov, NCT04345289, 14/04/2020. The CCAP-2 trial was terminated prematurely due to futility. Of 147 patients randomized, we included 144 patients in the modified intention-to-treat population. The ordinal clinical status 14 days post-intervention was comparable between treatment groups (odds ratio (OR) 1.41, 95% confidence interval (CI) 0.72–2.09). Results were consistent when evaluating clinical progression on an individual level 14 days after intervention (OR 1.09; 95% CI 0.46–1.73). No significant differences in length of hospital stay, admission to ICU, frequency of severe adverse events or all-cause mortality during follow-up were found between the intervention and the placebo group. Infusion of convalescent plasma did not influence clinical progression, survival or length of hospitalization in patients with COVID-19 pneumonia.

AB - Passive immunotherapy with convalescent plasma may be the only available agent during the early phases of a pandemic. Here, we report safety and efficacy of high-titer convalescent plasma for COVID-19 pneumonia. Double-blinded randomized multicenter placebo-controlled trial of adult patients hospitalized with COVID-19 pneumonia. The intervention was COVID-19 convalescent plasma and placebo was saline allocated 2:1. The primary outcome was clinical status 14 days after the intervention evaluated on a clinical ordinal scale. The trial was registered at ClinicalTrials.Gov, NCT04345289, 14/04/2020. The CCAP-2 trial was terminated prematurely due to futility. Of 147 patients randomized, we included 144 patients in the modified intention-to-treat population. The ordinal clinical status 14 days post-intervention was comparable between treatment groups (odds ratio (OR) 1.41, 95% confidence interval (CI) 0.72–2.09). Results were consistent when evaluating clinical progression on an individual level 14 days after intervention (OR 1.09; 95% CI 0.46–1.73). No significant differences in length of hospital stay, admission to ICU, frequency of severe adverse events or all-cause mortality during follow-up were found between the intervention and the placebo group. Infusion of convalescent plasma did not influence clinical progression, survival or length of hospitalization in patients with COVID-19 pneumonia.

U2 - 10.1038/s41598-022-19629-z

DO - 10.1038/s41598-022-19629-z

M3 - Journal article

C2 - 36180450

AN - SCOPUS:85139139930

VL - 12

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 16385

ER -

ID: 323842947